Jpmorgan Chase & CO Codiak Bio Sciences, Inc. Transaction History

Jpmorgan Chase & CO

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 13, 2023	SELL	$0.32 - $0.9 $415 - $1,169	-1,299 Reduced 94.27%	79 $0
Q3 2022 Nov 14, 2022	BUY	$0.82 - $3.19 $417 - $1,623	509 Added 58.57%	1,378 $1,000
Q2 2022 Aug 11, 2022	SELL	$2.24 - $6.96 $20,623 - $64,080	-9,207 Reduced 91.38%	869 $3,000
Q1 2022 May 11, 2022	BUY	$4.3 - $12.95 $9,692 - $29,189	2,254 Added 28.82%	10,076 $63,000
Q4 2021 Feb 10, 2022	SELL	$10.0 - $16.78 $24,760 - $41,547	-2,476 Reduced 24.04%	7,822 $87,000

Q3 2021 Nov 12, 2021	BUY	$15.58 - $22.88 $160,442 - $235,618	10,298 New	10,298 $168,000

238K

Ticker CDAK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 35,995,200
Market Cap $360K
Description
Codiak BioSciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing exosome-based therapeutics for the treatment of oncology, neuro-oncology, neurology, neuromuscular diseases, infectious diseases, and other diseases. Its lead product candidates are exoSTING and exoIL-12 exosome therapeutic candidates for the treatment of...

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

Stay updated on Jpmorgan Chase & CO with notifications on news.